Evaluation and Management of Hyponatremia in Patients Taking Tirzepatide (Zepbound)
Immediately discontinue tirzepatide if hyponatremia develops, as emerging case reports demonstrate tirzepatide can cause SIADH (syndrome of inappropriate antidiuresis) leading to severe, symptomatic hyponatremia including seizures. 1, 2
Initial Evaluation
When hyponatremia is detected in a patient on tirzepatide, perform the following diagnostic workup:
Step 1: Confirm True Hyponatremia
- Measure serum osmolality to exclude pseudohyponatremia
- If serum osmolality < 275 mOsm/kg, proceed with evaluation 3
Step 2: Assess Symptom Severity
Severe symptoms (seizures, somnolence, obtundation, coma, cardiorespiratory distress):
- This is a medical emergency requiring immediate hypertonic saline 4
Moderate symptoms (nausea, confusion, headache):
- Consider hypertonic saline or proceed with diagnostic evaluation 3
Asymptomatic or mild symptoms:
- Prioritize diagnostic assessment over immediate correction 3
Step 3: Measure Urine Studies
- Urine osmolality: If > 100 mOsm/kg, suggests impaired water excretion 3
- Urine sodium: If ≥ 30 mmol/L with euvolemia, suggests SIADH 3
Step 4: Assess Volume Status
Examine for:
- Hypovolemia: Orthostatic hypotension, decreased skin turgor, low jugular venous pressure 3
- Euvolemia: No edema, normal jugular venous pressure (most consistent with tirzepatide-induced SIADH) 1
- Hypervolemia: Peripheral edema, elevated jugular venous pressure 3
Step 5: Confirm SIADH Diagnosis
SIADH criteria in tirzepatide patients 3:
- Serum osmolality < 275 mOsm/kg
- Urine osmolality > 100 mOsm/kg
- Urine sodium > 30 mmol/L
- Clinical euvolemia
- Exclude adrenal insufficiency, hypothyroidism, and other medications causing SIADH
Critical caveat: Check for concomitant thiazide diuretics, as the combination with tirzepatide significantly increases hyponatremia risk 2. Consider measuring fractional uric acid excretion (FEUA > 12%) to differentiate SIADH from diuretic-induced hyponatremia 3.
Management Algorithm
For Severe Symptomatic Hyponatremia (Medical Emergency)
Administer hypertonic saline (3%) immediately to increase serum sodium by 4-6 mmol/L within 1-2 hours 5, 3, 4:
- Give 100-150 mL bolus of 3% saline over 10-20 minutes
- Recheck sodium 1 hour after first dose 3
- Repeat bolus if symptoms persist and target not reached
- Stop tirzepatide immediately 1
Correction limits to prevent osmotic demyelination syndrome:
- ≤ 10 mmol/L in first 24 hours 5, 3
- ≤ 18 mmol/L in first 48 hours 5, 3
- For high-risk patients (sodium ≤ 105 mmol/L, alcoholism, malnutrition, liver disease, hypokalemia): ≤ 8 mmol/L in 24 hours 5, 6
Monitor sodium every 6 hours during active correction 3.
For Asymptomatic or Mild Hyponatremia
- Discontinue tirzepatide immediately 1, 2
- Stop all non-essential medications that contribute to hyponatremia, particularly thiazide diuretics if blood pressure allows 3, 2
- Implement fluid restriction to < 800-1000 mL/day 3
- Monitor sodium daily until stable
Do not aggressively correct asymptomatic chronic hyponatremia with hypertonic saline, as there is insufficient evidence this improves outcomes and risks overcorrection 3.
If Overcorrection Occurs (> 10-12 mmol/L in 24 hours)
Immediately implement re-lowering strategy 3:
- Stop all sodium-containing fluids
- Administer 5% dextrose solution (10 mL/kg over 1 hour)
- Consider desmopressin 2 μg IV every 8 hours 3
- Monitor sodium every 2-4 hours
This is critical because osmotic demyelination syndrome can cause permanent neurological damage including quadriparesis and death 5, 4.
Key Clinical Pitfalls
Pitfall 1: Assuming GLP-1 receptor agonists are safe regarding electrolytes. Tirzepatide can cause SIADH even in previously healthy individuals without risk factors 1.
Pitfall 2: Continuing tirzepatide while treating hyponatremia. The drug must be discontinued as it is the causative agent 1, 2.
Pitfall 3: Combining tirzepatide with thiazide diuretics without sodium monitoring. This combination dramatically increases hyponatremia risk 2.
Pitfall 4: Overcorrecting chronic hyponatremia too rapidly. Even mild hyponatremia increases mortality risk 3, but overly rapid correction causes osmotic demyelination syndrome 5, 4.
Monitoring After Resolution
- Do not restart tirzepatide, as recurrence is likely 2
- If weight loss medication is still desired, consider alternative agents without SIADH risk
- Monitor sodium weekly for 4 weeks after resolution to ensure stability
The evidence for tirzepatide-induced hyponatremia is emerging but compelling, with multiple case reports demonstrating severe SIADH requiring hospitalization 1, 2. While the FDA label for Zepbound does not specifically list hyponatremia as an adverse effect 7, clinical vigilance is warranted given these recent reports.